Henry J A, Hennessy C, Levett D L, Lennard T W, Westley B R, May F E
University Department of Pathology, Royal Victoria Infirmary, Newcastle Upon Tyne, UK.
Int J Cancer. 1993 Mar 12;53(5):774-80. doi: 10.1002/ijc.2910530512.
Amplification of the int-2 oncogene was measured in a series of breast tumours and related to amplification of the c-myc and c-erbB-2 oncogenes, histopathological features and relapse-free and overall survival. int-2 was amplified in 11%, c-myc in 20% and c-erbB-2 in 27% of the tumours assessed. int-2 amplification was associated with large tumour size (p < 0.05) and reduced relapse-free (p < 0.05) and overall (p < 0.0005) survival. c-myc amplification was associated with poor tumour differentiation (p < 0.05) but had no association with prognosis. c-erbB-2 amplification was associated with low levels of expression of oestrogen receptor mRNA (p < 0.05), poor tumour differentiation (p < 0.05) and shortened relapse-free (p < 0.0001) and overall survival (p < 0.0001). This is the first report of an association between amplification of the int-2 oncogene in breast tumours and a significantly increased risk of death from breast cancer, and suggests that int-2 may be useful for identifying breast-cancer patients having a poor prognosis.
在一系列乳腺肿瘤中检测了int-2癌基因的扩增情况,并将其与c-myc和c-erbB-2癌基因的扩增、组织病理学特征以及无复发生存期和总生存期进行关联分析。在评估的肿瘤中,11%的肿瘤int-2基因发生扩增,20%的肿瘤c-myc基因发生扩增,27%的肿瘤c-erbB-2基因发生扩增。int-2基因扩增与肿瘤体积较大(p<0.05)以及无复发生存期(p<0.05)和总生存期(p<0.0005)缩短相关。c-myc基因扩增与肿瘤分化差(p<0.05)相关,但与预后无关。c-erbB-2基因扩增与雌激素受体mRNA低表达水平(p<0.05)、肿瘤分化差(p<0.05)以及无复发生存期(p<0.0001)和总生存期(p<0.0001)缩短相关。这是关于乳腺肿瘤中int-2癌基因扩增与乳腺癌死亡风险显著增加之间关联的首次报道,提示int-2可能有助于识别预后不良的乳腺癌患者。